Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ernexa Therapeutics Inc.
Report date August 08, 2023 · Filed August 10, 2023
Section 16 reporting ended · disclosed 2023-08-10. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2023 Filed Jul 18, 2023 20:15 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | PurchaseWarrants (right to buy) · Derivative | 83,916 | $0.13 Strike: $2.61 | $10,489.50 |
DisclosureSEC source: 0001140361-23-034994 · form4.xml · derivative · entry 2 WAGNER RICHARD W · CIK 0001277280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,916 Underlying: Common Stock · 83,916 shares Expires 2028-07-14 F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules. Read SEC document |
| July 13, 2023 Filed Jul 18, 2023 20:15 UTC | Ernexa Therapeutics Inc. ERNA · Entity 8278 | Purchase6.0% Senior Convertible Promissory Notes due 2028 · Derivative | Not disclosed | $120,000.00 Strike: $2.86 | $120,000.00 |
DisclosureSEC source: 0001140361-23-034994 · form4.xml · derivative · entry 1 WAGNER RICHARD W · CIK 0001277280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 41,958 shares Expires 2028-07-14 F1 · price: The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.